Saurabh Zanwar, Assistant Professor at Mayo Clinic, shared on X:
”Excellent paper by the Abdel-Wahab Lab describing resistance to BTK degraders being driven by a novel BTK A428D mutation, which worryingly also confers cross resistance to all existing BTK inhibitors.
Important sequencing implications on treatement for wmsm.
Interesting to see the reduced expansion of the clone with concurrent BCL2 inhibition.
Yucai Wang is leading a BTK degrader + sonrotoclax study in various lymphomas with a sub-arm of Waldenstrom macroglobulinemia.”
Other articles featuring Saurabh Zanwar on OncoDaily.